Timing is everything: assessing the impact of maternal HIV infection diagnosis timing on infant outcomes in a ten-year retrospective cohort study in South Carolina

Cohn, Ellery; Korte, Jeffrey E.; Lazenby, Gweneth B.

doi:10.1080/09540121.2019.1707470

Cited by 1 publication

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, our sample size calculation was made using data from a previous study of SC eHARS data in which we observed a much lower percentage of women with viral suppression before delivery (40%). [20][21][22]26 As a result, we found an unexpectedly high percentage of women had viral suppression on a non-INSTI regimen (73%). This percentage of women observed to have viral suppression before delivery was similar to previous reports evaluating INSTI use during pregnancy.…”

Section: Discussionmentioning

confidence: 99%

“…A post hoc sample size calculation was based on our previous observations from the SC DHEC eHARS database. [20][21][22] We assumed 40% of women with HIV prescribed non-INSTI ART would have HIV RNA , 40 copies/mL before delivery. Using our institution's data on viral suppression before delivery in pregnant women on INSTI, 16 we assumed 75% of women with HIV prescribed INSTI would have HIV RNA , 40 copies/mL.…”

Section: Sample Size Calculationmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Integrase Strand Transfer Inhibitor Use During Pregnancy on Viral Suppression at Delivery and Infant Outcomes: A Statewide Retrospective Cohort Study

Latham

Nissim

Spitznagel

et al. 2022

JAIDS Journal of Acquired Immune Deficiency Syndromes

Self Cite

View full text Add to dashboard Cite

Background:We sought to determine whether pregnant women with HIV prescribed integrase strand transfer inhibitor (INSTI) were more likely to have viral suppression at delivery and any increased risk of adverse infant outcomes.Methods: This was a retrospective, statewide cohort study of women with HIV and their HIV-exposed infants who delivered in South Carolina from 2008 to 2019. Women's antenatal AVRs were classified as INSTI or non-INSTI. We compared the percentage of women with undetectable HIV RNA viral load (,40 copies/mL) at delivery between groups. We compared the percentage of HIVexposed singleton infants who were born preterm delivery, low birth weight, and small for gestational age and had confirmed perinatal HIV infection. Categorical outcomes were compared using the x 2 test or Fischer exact test.Results: A total of 832 infants, including 11 sets of twins, were exposed to maternal HIV. Detailed antiretroviral regimens were available for analysis in a third of mother-infant pairs (n = 315). Half of the infants were exposed to INSTI (159) and half to non-INSTI antiretrovirals (156). Most women had an undetectable viral load at delivery (80% INSTI and 73% non-INSTI, P= 0.11). The percentage of singleton infants with adverse outcomes was similar between INSTI and non-INSTI groups: preterm delivery (21% and 16%, P = 0.3), low birth weight (19% and 21%, P = 0.7), small for gestational age (11% vs 9%, P = 0.5), and perinatal HIV infection (2.5% and 1.3%, P = 0.7). Conclusions:We observed that viral suppression before delivery was similar between pregnant women prescribed INSTI and non-INSTI antiretroviral therapy. The percentage of infants with adverse outcomes was similar when exposed to INSTI and non-INSTI antiretroviral therapy.

show abstract

Section: Discussionmentioning

confidence: 99%